Organon & Co. (LON:0A9W)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.47B -55.9% |
| Revenue (ttm) | 4.69B -1.7% |
| Net Income | 372.71M -61.5% |
| EPS | 1.42 -62.1% |
| Shares Out | n/a |
| PE Ratio | 3.93 |
| Forward PE | 2.14 |
| Dividend | 0.27 (3.48%) |
| Ex-Dividend Date | Nov 20, 2025 |
| Volume | 2,918 |
| Average Volume | 23,039 |
| Open | 7.72 |
| Previous Close | 7.96 |
| Day's Range | 7.67 - 7.80 |
| 52-Week Range | 6.20 - 17.20 |
| Beta | 0.54 |
| RSI | 40.05 |
| Earnings Date | Feb 12, 2026 |
About Organon & Co.
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to... [Read more]
Financial Performance
In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.
Financial numbers in USD Financial StatementsNews
What Does the Market Think About Organon & Co?
Organon & Co's (NYSE: OGN) short interest as a percent of float has risen 5.76% since its last report. According to exchange reported data, there are now 17.55 million shares sold short , which is 9....
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces date for Q4 and FY2025 earnings results conference call will be February 12, 2026 at 8:30am EST.
Organon (OGN) Completes Sale of JADA System to Laborie Medical
Organon (OGN) Completes Sale of JADA System to Laborie Medical
Organon Completes Divestiture of JADA® System to Laborie
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp.
Stone House Investment Management, LLC Buys 1,274 Shares of Organon & Co (OGN)
Stone House Investment Management, LLC Buys 1,274 Shares of Organon & Co (OGN)
Independence Bank of Kentucky Sells 500 Shares of Organon & Co (OGN)
Independence Bank of Kentucky Sells 500 Shares of Organon & Co (OGN)
Organon Secures FDA Approval Extending NEXPLANON Use to Five Years
OGN wins FDA approval to extend NEXPLANON use to five years, backed by trials showing no pregnancies and strong efficacy across body weights.
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN), a U.S.-based women's healthcare company. If it goes through, the deal that ...
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN), a U.S.-based women's healthcare company.
Organon (OGN) Shares Surge on Acquisition Offer from Sun Pharma
Organon (OGN) Shares Surge on Acquisition Offer from Sun Pharma
Organon gains on report of Sun Pharmaceutical interest
Organon (OGN) Gains FDA Approval to Extend Nexplanon Usage Duration
Organon (OGN) Gains FDA Approval to Extend Nexplanon Usage Duration
FDA Extends Nexplanon Use to Five Years, Boosts Organon (OGN) Prospects
FDA Extends Nexplanon Use to Five Years, Boosts Organon (OGN) Prospects
Organon wins FDA nod to expand use of Nexplanon birth control implant
FDA Approves Organon's SNDA Extending NEXPLANON Use To Five Years With New REMS Program
(RTTNews) - Organon (OGN) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON (etonogestrel implant). NEXPLANON is indicate...
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's NEXPLANON receives U.S. FDA sNDA approval for extended duration of use up to five years, including data for use in women with varying BMIs.
Organon (OGN) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Organon (OGN) stood at $8.7, denoting a +1.05% move from the preceding trading day.
Organon (OGN) Shares Climb Amid Mixed Analyst Ratings
Organon (OGN) Shares Climb Amid Mixed Analyst Ratings
Organon poised to extend rally to seventh consecutive session
Organon (OGN) Partners with Daiichi Sankyo Europe to Launch Nilemdo in Nordic Regions
Organon (OGN) Partners with Daiichi Sankyo Europe to Launch Nilemdo in Nordic Regions
Organon gets Nordic and French rights to commercialize Nilemdo for dyslipidemia
Organon (OGN) Partners with Daiichi Sankyo Europe to Distribute Nilemdo
Organon (OGN) Partners with Daiichi Sankyo Europe to Distribute Nilemdo
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio.
Organon Named Top Dividend Stock With Insider Buying and 0.99% Yield (OGN)
In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. ...
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Organon (OGN) closed at $6.98, marking a +2.2% move from the previous day.